Galapagos Keeps Analysts Guessing About Future Plans
As JAK Inhibitor Jyseleca Beats Forecasts
Executive Summary
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.